
Shares of Ocugen Inc (NASDAQ:OCGN) are trading lower by more than 8% Monday afternoon. The company earlier announced a definitive agreement to merge its subsidiary OrthoCellix with Carisma Therapeutics in an all-stock deal.
What To Know: Under the agreement signed June 22, OrthoCellix, holder of Ocugen's NeoCart regenerative medicine assets, will merge with a Carisma subsidiary, becoming a wholly owned subsidiary of Carisma.